Vernalis Pharmaceuticals Inc.
Division of Ligand Pharmaceuticals Inc.
Latest From Vernalis Pharmaceuticals Inc.
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.
Novartis’ targeted combination strategy in particular leverages its “strong” pipeline in agents acting on the PI3K, RAS, RAF and MEK pathways.
Financings Of The Fortnight: Big FOPO For Troubled Alnylam, Plus First European IPO Of 2012 For Adocia
Plus news on recent financing by Satori, Ceptaris, Vernalis and Exelixis
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.